Wilson Sonsini Goodrich & Rosati advised Bolt Medical on the transaction. Boston Scientific (NYSE: BSX) announced it has entered into a definitive agreement to acquire Bolt...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised USANA Health Sciences, while Bodman PLC acted as Hiya’s legal advisor. Fried Frank acted as counsel to BofA Securities as...
You must be a Standard 1 Year member to access this content.
Gibson Dunn & Crutcher advised Merck on the transaction and Wilson Sonsini Goodrich & Rosati advised LaNova Medicines. Merck (NYSE: MRK), known as MSD outside of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Circle Pharma on the transaction. Circle Pharma (Circle), a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Boston Scientific Corporation in the transaction, and Wilson Sonsini Goodrich & Rosati represented Silk Road Medical. Boston Scientific Corporation (“Boston Scientific”) (NYSE:...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Insilico in the transaction. Stemline Therapeutics, Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology...
You must be a Standard 1 Year member to access this content.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo advised Amring Pharmaceuticals Inc. on the transaction, and Wilson Sonsini Goodrich & Rosati advised Visant Medical. Amring Pharmaceuticals Inc....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised BioMap on the transaction. BioMap announced a collaboration with Sanofi, to co-develop advanced AI modules for biotherapeutic drug discovery leveraging BioMap’s...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Exelixis, Inc. and Insilico Medicine announced that they have entered into an exclusive license agreement granting Exelixis...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Insilico Medicine, a clinical-stage artificial intelligence-driven drug discovery company, announced a multi-year, multi-target strategic research...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini advised Enliven Therapeutics on the deal. Enliven Therapeutics, a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised LaNova on the deal. Turning Point Therapeutics, Inc., a clinical-stage precision oncology company designing and developing novel targeted therapies for...
You must be a Standard 1 Year member to access this content.
